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jhuapl.edu (H. Burkom), jit1@cdc.gov (J. Tokars).Background: Automated surveillance systems require statistical methods to recognize increases in visit
counts that might indicate an outbreak. In prior work we presented methods to enhance the sensitivity
of C2, a commonly used time series method. In this study, we compared the enhanced C2 method with
ﬁve regression models.
Methods: We used emergency department chief complaint data from US CDC BioSense surveillance sys-
tem, aggregated by city (total of 206 hospitals, 16 cities) during 5/2008–4/2009. Data for six syndromes
(asthma, gastrointestinal, nausea and vomiting, rash, respiratory, and inﬂuenza-like illness) was used and
was stratiﬁed by mean count (1–19, 20–49, P50 per day) into 14 syndrome-count categories. We com-
pared the sensitivity for detecting single-day artiﬁcially-added increases in syndrome counts. Four mod-
iﬁcations of the C2 time series method, and ﬁve regression models (two linear and three Poisson), were
tested. A constant alert rate of 1% was used for all methods.
Results: Among the regression models tested, we found that a Poisson model controlling for the loga-
rithm of total visits (i.e., visits both meeting and not meeting a syndrome deﬁnition), day of week, and
14-day time period was best. Among 14 syndrome-count categories, time series and regression methods
produced approximately the same sensitivity (<5% difference) in 6; in six categories, the regression
method had higher sensitivity (range 6–14% improvement), and in two categories the time series method
had higher sensitivity.
Discussion: When automated data are aggregated to the city level, a Poisson regression model that con-
trols for total visits produces the best overall sensitivity for detecting artiﬁcially added visit counts. This
improvement was achieved without increasing the alert rate, which was held constant at 1% for all meth-
ods. These ﬁndings will improve our ability to detect outbreaks in automated surveillance system data.
Published by Elsevier Inc.1. Introduction
Automated surveillance involves using algorithms to monitor
pre-existing datasets for evidence of disease outbreaks or trends.
Administrative data, such as the free text ﬁeld recording each pa-
tient’s chief complaint for the visit, are commonly used. These chief
complaint strings are used to classify the records according to a set
of disease types or syndrome groupings, denoted simply as syn-
dromes in the discussion to follow. For example, a record with a
chief complaint of ‘‘deep cough with chills’’ could be classiﬁed in
the respiratory syndrome. For each syndrome, daily counts of re-
cords are stored and combined to form syndromic time series,
i.e., syndrome counts plotted over time. These time series are mon-Inc.
d NE, MS G-37, Atlanta, GA
(J. Xing), Howard.Burkom@itored using automated statistical algorithms for increases that are
anomalous compared to expected or modeled behavior [1–4]. Typ-
ically, monitoring for increased counts on a given index day in-
volves calculating the expected number of visits on the day,
assuming no outbreak, and comparing this expected value to the
count actually observed.
Themeasures customarily used in epidemiology, incidence rates
of disease in the population at risk, are not available in automated
surveillance. Instead, automated surveillance aims to measure
changes in healthcare behavior, such as visits to an emergency
department. Since a true denominator is not available to calculate
disease incidence, simple counts (numerator data) are often moni-
tored. An alternative is to use as a surrogate rate the proportion of
total visits that are classiﬁed into a given syndrome. The ‘‘C2-rate’’
method [5] is an implementation of this approach. This method
involves calculating the expected number of visits for a given
syndrome on an index day as follows: summing the visits for the
syndrome over the recent 2–4 weeks, summing total visits over
1094 J. Xing et al. / Journal of Biomedical Informatics 44 (2011) 1093–1101the same time period, calculating the proportion of total visits that
were for the syndrome, andmultiplying this proportion by the total
number of visits on the index day. This method was shown to pro-
duce more accurate expected values and better sensitivity for
detecting an increased number of visits than basing expected val-
ues on the simple mean number of recent visits for the syndrome.
Our previous work on comparison of regression models to con-
trol charts, using syndromic ED time series collected by the Bio-
Sense surveillance system [6] operated by the US Centers for
Disease Control and Prevention (CDC), was reported [7]. Except
for the broadest syndrome groupings at large facilities, daily syn-
dromic time series at the facility level are often sparse, with many
daily counts of zero. The rationale for using regressionmodeling for
surveillance is to capture systematic data effects such as trends or
cycles so that algorithms applied to forecast residuals are not biased
by these effects [8]. However, the sparseness of day-of-week and
seasonal effects at the facility level does not work well for regres-
sion [7]. The widely used Serﬂing models are generally applied at
the city level or higher [9]. Therefore, the series examined in this
manuscript were restricted to the level of the Metropolitan Report-
ing Area (MRA) including visits from multiple facilities. The regres-
sion variables described in the methods were based on earlier
ﬁndings with the same data [7]. The current study includes ex-
panded methods applied to a more extensive set of syndromic time
series with more rigorous statistical examination.
In this work we applied alerting algorithms to regionally dis-
tributed time series and report ﬁndings from a biosurveillance
model comparison study. The objective of the study was to select
the most appropriate statistical alerting algorithms for monitoring
of disparate surveillance data types at distributed sites. This dis-
tributed monitoring should be robust in that (a) forecast and
anomaly detection methods are appropriate for the various time
series of interest, and (b) the detection performance, measured
by sensitivity and background alert rate, is consistent across data
types and monitoring sites.2. Methods
2.1. Description of study data
Study data were taken from the CDC BioSense automated bio-
surveillance system. This system includes emergency department
records with a free text ﬁeld for the patient’s chief complaint dur-
ing the visit. We chose hospital Emergency Department free-text
chief complaint data sent by 258 non-federal hospitals nationwide.
Each hospital belongs to one of 48 Metropolitan Reporting Areas
(MRA). Each MRA includes between 1 and 39 hospitals. For our
study we chose 16 MRAs such that the data reported by each
MRA included at least ﬁve hospitals (total of 206 hospitals) and
such that the proportion of unreported historical data days was
<1%. To study model forecast and detection performance over a
variety of data scales, seasonal behaviors, and regions, we selected
six BioSense syndromes and sub-syndromes [6,16]. The Gastroin-
testinal syndrome and the Nausea and Vomiting sub-syndrome
were reported in high counts from most hospitals. The Respiratory
syndrome and Inﬂuenza-like illness (ILI) sub-syndrome show a
seasonal pattern. The Asthma sub-syndrome, a subset of the Respi-
ratory syndrome, was reported in low counts from most hospitals.
Finally, the Rash syndrome has intermediate visit counts.
The study period was 5/1/2008–4/30/2009. We used data from
a 56-day baseline period to compute regression coefﬁcients. Thus
the baseline period for the ﬁrst test day began on 3/4/2008. For
coefﬁcients reﬂecting recent data behavior and including the data
from hospitals providing data in recent weeks, we used a sliding
baseline, so that each baseline period ended 2 days before the datewhose data was tested for an anomaly. The purpose of the 2-day
buffer was to avoid contamination of the baseline data by the early
phases of an outbreak. The data for this study were provided by 16
Metropolitan Reporting Areas (MRA). For those reports, initially,
we performed preliminary descriptive analysis that showed di-
verse mean count for different MRAs and syndrome. In improve
accuracy, we stratiﬁed the MRA into three levels, based on the
mean daily count: 1–19, 20–49 and P50.
2.2. Control-chart-based algorithms
BioSense uses a rate-based version of the C2 algorithm, one of
the three algorithms (C1, C2 and C3) developed for the Early Aber-
ration Reporting System (EARS) [10,11]. Our previous study [5] also
showed consistent improved sensitivity to simulated signals when
the length of the sliding baseline was increased from 7 days to 14
or 28 days. For comparison to regression models, we applied the
count-based and rate-based C2 algorithm using 14-day and 28-
day baselines, with the descriptive names C2c14, C2r14, C2c28
and C2r28.
Let L be length of baseline and let the index day be the day
whose data are being tested. Analogous to the sliding baseline used
to compute regression model coefﬁcients, the index day expected
value for syndromic visits was calculated using the 14-or 28-day
baseline, i.e. L = 14 or 28, separated from the index day by a
2-day buffer. For the count-based C2 methods, the expected value
is simply the mean baseline count. For the rate method, the ex-
pected value is:
Expectedindexday ¼ Nindexday 
PL
i¼1niPL
i¼1Ni
ð1Þ
where ni is number of visits meeting a syndrome deﬁnition on base-
line day i, Ni is number of total visits, Nindexday is number of total vis-
its on the test day.
For normalization of mean deviations, a dispersion measure for
rate-based C2 was calculated by
SDindexday ¼
PL
i¼1 ni  Ni 
PL
j¼1njPL
j¼1Nj


L
ð2Þ2.3. Regression-based models
The regression modeling was guided by the following ﬁndings
from [7]. First, seasonality is captured using indicator variables
rather than from models based on multiple years of data history
that are unavailable for many data streams. These indicator vari-
ables are given a ﬁxed value for each day of a time interval in-
tended to represent current seasonal behavior. Several interval
lengths were tested, and a 14-day interval gave the best forecasts
and is used in the models below. Second, sliding baselines for the
regression inference were limited to 56 days; longer baseline inter-
vals did not improve forecast accuracy. Third, use of total visits for
surrogate rates gave substantial forecast improvements in respira-
tory and gastrointestinal syndrome data for some time series, and
the models in the Methods use the total visits in several ways.
Fourth, the day-of-week indicator variables improved forecasts
for some syndromes and were used in the models tested. Experi-
ence with these ED data series shows weekly patterns for certain
syndrome groups, but holiday and post-holiday effects are not con-
sistent and were not modeled.
Our ﬁve regression models controlled for day of week (dow)
with indicator variables and seasonality with indicator variables
for 14-day time period. Three of the models also controlled for total
daily visits, which includes both baseline and the indexday (test
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tion of total number of visits on that day. We used SAS GENMOD to
performed expected value calculations.
Model 1 (Poisson regression) – the total number of visits was
modeled as a linear predictor:Expectedindexday ¼ b0 þ b1dowbaseline þ b214daybaseline
þ b3Nbaselineþindexdayjdis
¼ Poisson; link ¼ log
Model 2 (Poisson regression) – total visits was not included:
Expectedindexday ¼ b0 þ b1dowbaseline þ b214daybaselinejdis
¼ Poisson; link ¼ log
Model 3 (Linear regression) – total visits was modeled as a lin-
ear predictor:
Expectedindexday ¼ b0 þ b1dowbaseline þ b214daybaseline
þ b3Nbaselineþindexdayjdis
¼ normal; link ¼ identity
Model 4 (Linear regression) – total visits was not included:
Expectedindexday ¼ b0 þ b1dowbaseline þ b214daybaselinejdis
¼ normal; link ¼ identity
Model 5 (Poisson regression) – the log of total visits was used as
an offset:
Expectedindexday ¼ b0 þ b1dowbaseline þ b214daybaselinejdis
¼ Poisson; link ¼ log; offset
¼ logðNbaselineþindexdayÞ
The regression models were run separately for each MRA/syn-
drome combination, with the expected value for each index day
calculated from the regression coefﬁcients modeled from the pre-
vious 56 days of data, i.e. L = 56, with a 2-day buffer. The standard
deviation (SD) of the expected value was calculated by the follow-
ing equation [12]:SDindexday ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPL
i¼1½Observedi  Expectedindexday2
L k 1
s
ð3Þ
where the L equals the number of days in the baseline period and k
is number of independent variables (k = 3 for model 1 and 3, k = 2
for model 2, 4, and 5). The detection statistic, equation (4), was
computed by dividing the forecast residuals by this standard devi-
ation; to avoid division by small numbers and thus unreasonably
high statistic values, we used a minimum standard deviation of 1.0.
2.4. Threshold calculations
In general, the time series derived for biosurveillance monitor-
ing are not temporally independent and do not ﬁt a single proba-
bility distribution because of their heterogeneous nature and
because the quality of reporting is variable. Thus, a single probabil-
ity distribution function may not be used to derive an alerting
threshold. We therefore used historical data streams to derive
empirical alerting thresholds, using the recurrence interval con-
cept. The recurrence interval is deﬁned as the number of days
(more generally, uniformmeasurement intervals) for which the ex-
pected number of threshold crossings is 1 [15] and the empirical
daily probability of crossing the threshold is then 1/N. In this study,
we calculated thresholds for which N = 100 so that the daily alert
rate would be 1%. We chose the value 1% for convenient interpre-tation and because a background alert rate of approximately 1 in
3 months is a practical one for public health surveillance—not so
few that important increases will be missed, not so many that
alarms will be a nuisance. First, we calculated the test statistic,
z-score for each time series value;
z scoreindexday ¼
ðObservedindexday  ExpectedindexdayÞ
SDindexday
ð4Þ
For a given alerting method, we found too much variation among
the tails of the z-score distributions across syndrome groupings
and data scales to use a single threshold for all time series. After
considering several time series classiﬁcations, we chose to stratify
alerting thresholds by combinations of syndrome and mean levels.
For each such combination, we selected as a threshold the 99th per-
centile cutoff value of all z-scores for all corresponding MRA time
series over the study period. This procedure gave thresholds yield-
ing an overall daily alert rate of 1% for time series within each
combination.
2.5. Injection of added counts for sensitivity calculations
The time series effects of authentic outbreaks are difﬁcult to
ﬁnd in biosurveillance time series, except for obvious spikes for
which algorithms are not needed. Additionally, the algorithms
most widely used in global public health practice, e.g. those of
the EARS system [10] employed in many countries, are based on
single-day anomalies. Therefore, we added single-day increments
to the authentic data time series and compared the methods on
the derived series in order to measure and compare the sensitivity
of the algorithms. Given the large number of time series consid-
ered, the rare and unclear occurrence of outbreaks, and the fact
that we sought a relative comparison of method performance, we
did not attempt to discern or remove true outbreak signals from
this process. This study was limited to model comparison and
parameterization, not detection timeliness, so we did not inject
more complex multi-day signal shapes for which sensitivity would
also depend on how successive anomalies were combined.
The sensitivity measurement method was to inject single-day
counts into the time series for a number of trials, which was
counted based on the combination of the 365 injection days and
ﬁve different injection percentage levels for each syndrome/sub-
syndrome daily mean level. We estimated detection sensitivity
by calculating the fraction of those trials for which the z-score ex-
ceeded the threshold value explained above. Details are: (a) we
performed injection trials by adding extra counts to each time ser-
ies one day at a time; (b) on the selected day for each trial, the
number of added counts was a ﬁxed percentage of the mean of
counts for the 14 previous days; (c) the resulting sensitivity esti-
mates for all of the regression model and adaptive chart methods
were compared for the syndrome groups and MRA time series de-
scribed above; (d) for the C2-rate methods and regression models
1, 3, and 5, all of which use daily total visit counts, the additional
counts were added to both the numerator (syndromic counts)
and denominator (total visits). These sensitivity estimates were
compared for injection levels of 20%, 40%, 60%, 80%, and 100%.
2.6. Evaluations
We chose the evaluation measures in this study for relevance to
the distributed monitoring of syndromic time series data from the
BioSense system [16]. The measures were regression model predic-
tor evaluation tests, prediction capability tests, and outbreak
detection capability tests.
For the regression model predictor evaluation test, we calcu-
lated the percentage (%) of days when the individual covariate
Table 1
Mean counts grouped by syndrome and MRA mean level.
Syndrome Mean level Number of
MRAs
Mean daily
counts
Mean daily
visits
Asthma 1–19 10 8 823
Asthma 20–49 5 32 1869
Asthma P50 1 50 2633
Gastrointestinal 20–49 1 44 313
Gastrointestinal P50 15 208 1326
Nausea and vomiting 20–49 5 30 491
Nausea and vomiting P50 11 114 1614
Rash 1–19 7 12 632
Rash 20–49 8 33 1491
Rash P50 1 71 3853
Respiratory P50 16 262 1263
ILI 1–19 10 12 783
ILI 20–49 5 33 1741
ILI P50 1 95 3900
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(e.g., model 1-Asthma), we ran the algorithm for each individual
day. Next, we looked at the Wald Chi-Square test p-value for each
covariate per day, counted those with p6 0.05, and calculated the
percentage (%) of days where the covariate was signiﬁcant. The re-
sults of these tests were tabulated for 365 consecutive days, with
the 8-week sliding baseline beginning 58 days before the ﬁrst test
date, including the 2-day buffer. The day-of-week indicators were
assessed together with a single test.
For prediction capability testing, we calculated the mean abso-
lute residual without any injection. We deﬁne a residual Rj for a
forecast on day j as Rj = Oj  Ej, where Oj is the observed value
and Ej is the forecast. Thus, a positive residual means underesti-
mation of the observed value. The mean absolute residual for a
time series is the average value of Rj for all forecast days, so that
a low absolute residual value indicates a more accurate forecast
than a high one. For forecast methods that require an interval
for the initial inference, the analysis days do not include the en-
tire series. We used the mean absolute residual to evaluate the
accuracy of the expected value calculation for regression and
C2 models. This measure was used because the fractional (or per-
centage) error may be deceiving in comparing the forecast ability
for large- and small-count time series and because the scale of
the absolute error can be helpful in assessing the value of the
forecast. The mean absolute residual allows straightforward com-
parisons between methods at each level [17,18]. For the regres-
sion models, the expected value Ej was taken as the day-j
forecast using the calculated regression coefﬁcients, while for
the adaptive methods based on C2, Ej was the mean of the sliding
baseline.
For outbreak detection capability testing, at thresholds calcu-
lated for a constant alert rate of 1% (false positives per day) for
all methods, we calculated sensitivity as the percentage of days
with injected counts on which the algorithm output exceeded
the corresponding threshold, triggering an alert and focusing
attention for potential investigation.3. Results
3.1. Descriptive data
Among 14 categories deﬁned by syndrome and mean visit
count, the number of MRAs varied from 1 to 16, mean daily count
from 8 to 262, and mean daily total visits from 313 to 3900 (Table
1). Some examples of time series charts for selected syndromes and
MRAs are shown in Fig. 1.3.2. Model variable signiﬁcance
The daily total visits covariate in models 1 and 3 was signiﬁcant
on 66.7–100% of days across the syndrome groups (Table 2), and
was signiﬁcant in over 90% of the days for syndromes associated
with seasonal viruses (i.e., Gastrointestinal, Nausea and Vomiting,
Respiratory, and ILI). Even for the Asthma and Rash groups, which
included sparse time series at mean level 1–19, total visits were
signiﬁcant on more than 2/3 of the run-days for applicable models.
For all the models, the Dow and 14-day indicator variables were
signiﬁcant consistently more often when the total visits variable
was not included (Table 2). For example, for the Poisson models,
the 14-day indicators were signiﬁcant in the Asthma and Gastroin-
testinal time series for 27.4% and 47.2% of the runs for model 1 (to-
tal visits included) but in 34.5% and 70.4% of the runs for model 2
(total visits not included). The reduced percentage of signiﬁcant
days when total visits are added is likely because the total visits
alone account for some of the weekly and seasonal changes ad-dressed by the two indicator variables. However, even in models
1 and 3, which include total visits, the indicator variables are sig-
niﬁcant for most of days among the entire MRA-study period for
all of the syndrome groups. The 14-day indicator was signiﬁcant
more often for syndromes with expected virus-related seasonal
patterns, e.g. ILI and Respiratory, than for other groups.3.3. Model forecast accuracy
The mean absolute residuals show that all methods using total
visits (C2r14, C2r28, models 1, 3 and 5) had much better prediction
ability than did methods not using total visits (Table 3). For exam-
ple, for Poisson models applied to the Respiratory syndrome, the
mean residuals were 19.87 and 17.81 for models 1 and 5 (which in-
clude total visits) but increased to 37.81 for model 2 (does not in-
clude total visits).
We also found that the mean absolute residual increased with
the MRA-series mean for all disease/syndrome groups (Table 3).
For example, for mean level 1–19, the mean absolute residuals
for the Asthma group were 2.30 for both C2r14 and C2r28, and they
increased to 7.28 (217%) and 7.43 (223%), respectively, for mean le-
vel P50. This ﬁnding indicated that for distributed monitoring
sites with different mean levels, we would expect corresponding
levels of mean absolute residual. Finally, model 5 gave the lowest
residual values for 5 of the MRA-based disease/syndrome catego-
ries P50. This result suggests that using an offset to model the
count/visit proportion generally provides more accurate forecasts
than modeling counts using total visits as a covariate.3.4. Signal sensitivity
Sensitivity was compared among the algorithms using a back-
ground alert rate of 1 threshold crossing per 100 days. The empir-
ical thresholds used to achieve this alert rate are shown in Table 4.
Overall, model 5 gave the best performance. Consistent with the
forecast comparisons, methods using the total visits covariate
had higher sensitivity than those using pure counts, i.e. C2r14
and C2r28 detected more signals than C2c14 and C2c28, and mod-
els 1, 3 and 5 outperformed models 2 and 4 (Table 5). Sensitivity
increased with the MRAmean level, with the exception of mean le-
vel P50 for the ILI-mean syndrome; the minimum increase was
17% (from 25% to 42%) for Rash with C2c28 method, and maximum
increase was 81% (from 16% to 97%) for Asthma with regression
model 5. For most of the syndrome groups, the maximum sensitiv-
ity is consistently above 95% for level 3 (time series with daily
mean above 50), but the choice of method may be important; for
example, the rate-based regression models applied to the Rash ser-
(a) Asthma, MRA #4 
(b) Gastrointestinal, MRA #1 
(c) Respiratory, MRA #12 
(d) ILI, MRA #8 
Fig. 1. Shows some sample time series of daily visit counts for these syndromes.
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Sensitivity is consistently below 30% for mean level 1–19; this re-sult is expected because few counts are injected for the sparser ser-
ies on some days.
Table 2
Percentage (%) of signiﬁcance day of entire MRA-study period based on Wald Chi-
Square test (p 6 0.05) for individual covariate in a speciﬁc model-syndrome set.
Model Syndrome Covariates signiﬁcant (day%)
Dow 14-day Total visits*
Model 1 Asthma 23.4 27.4 66.7
Model 1 Gastrointestinal 40.7 47.2 97.4
Model 1 Nausea and vomiting 40.3 56.7 93.8
Model 1 Rash 37.3 26.6 75.8
Model 1 Respiratory 37.3 85.5 100.0
Model 1 ILI 66.5 90.9 97.6
Model 2 Asthma 58.5 34.5 n/a
Model 2 Gastrointestinal 97.0 70.4 n/a
Model 2 Nausea and vomiting 88.9 72.2 n/a
Model 2 Rash 55.8 42.3 n/a
Model 2 Respiratory 100.0 99.4 n/a
Model 2 ILI 84.9 98.6 n/a
Model 3 Asthma 30.8 29.2 69.8
Model 3 Gastrointestinal 35.9 45.6 99.2
Model 3 Nausea and vomiting 34.9 52.8 94.6
Model 3 Rash 46.0 26.8 75.2
Model 3 Respiratory 46.8 89.1 100.0
Model 3 ILI 54.6 92.9 95.8
Model 4 Asthma 50.4 32.5 n/a
Model 4 Gastrointestinal 84.7 44.0 n/a
Model 4 Nausea and vomiting 60.5 54.0 n/a
Model 4 Rash 45.6 34.1 n/a
Model 4 Respiratory 96.2 97.2 n/a
Model 4 ILI 69.2 96.8 n/a
Model 5 Asthma 25.0 29.8 n/a
Model 5 Gastrointestinal 36.3 49.4 n/a
Model 5 Nausea and vomiting 39.7 58.3 n/a
Model 5 Rash 42.3 28.6 n/a
Model 5 Respiratory 46.6 90.9 n/a
Model 5 ILI 72.6 95.8 n/a
* Note that models 2 and 4 do not include total visits, and 5 used total visits as a
multiplicative offset and not as a predictor variable, as indicated by the corre-
sponding n/a entries.
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ity minus the highest sensitivity for each syndrome-mean count
combination (Table 6). For most, this value was best for C2r28
among control-chart-based methods, and for model 5 among
regression models. The sensitivity of model 5 wasP5% higher than
that of C2r28 for 6 of the 14 rows; the C2r28 model wasP5% high-
er for 2 rows, and the two were similar for 6 rows. The sensitivity
for model 5 was low for the ILI series even though the model-5
forecast accuracy for those series (Table 4) was the best for mean
level 20–49 and second only to model 1 for mean level P50.
Fig. 2 gives summary bar chart comparisons of method sensitiv-
ity averaged over all time series by injection percentage. For theTable 3
Mean absolute residual per syndrome-MRA mean level-day. Emboldened values are withi
Syndrome Mean level Mean absolute residual
C2c14 C2r14 C2c28 C2r28
Asthma 1–19 2.63 2.30 2.61 2.30
Asthma 20–49 6.98 5.58 7.18 5.86
Asthma P50 9.09 7.28 9.12 7.43
Gastrointestinal 20–49 9.55 5.70 10.24 5.68
Gastrointestinal P50 29.04 14.06 29.14 14.30
Nausea and vomiting 20–49 6.09 4.74 6.19 4.78
Nausea and vomiting P50 17.82 10.67 18.11 11.09
Rash 1–19 3.61 3.07 3.54 3.03
Rash 20–49 7.02 5.64 6.95 5.64
Rash P50 14.54 8.99 14.57 8.94
Respiratory P50 39.20 18.20 40.17 19.98
ILI 1–19 3.88 3.50 4.14 3.74
ILI 20–49 8.10 6.92 8.96 7.70
ILI P50 23.26 17.35 27.35 21.85more easily detected signals at higher inject percentages, perfor-
mance of the C2r14 and C2r28 models is similar to those of regres-
sion models 3 and 5, but the regression models outperform the C2
models for lower inject percentages that are more difﬁcult to de-
tect. Again model 5, the Poisson regression with total visits as an
offset, slightly outperforms the other regression models.
The sensitivity comparison bar charts in Fig. 3 show how sensi-
tivities vary by disease/syndrome group at mean levelP50 and at
40% injection. Sensitivity was lowest for ILI and highest for Gastro-
intestinal in all methods. Again, methods using total visits (C2r14,
C2r28, model 1, 3 and 5) had higher sensitivity than the corre-
sponding methods based only on syndrome counts. Note the low
ILI sensitivities combined with the algorithm performance compar-
ison that is dissimilar from that within other syndrome groups.
3.5. Relationship between forecast accuracy and signal sensitivity
The previous tables compared the algorithms separately for
forecast accuracy and for detection sensitivity. We were concerned
that differences among the methods in forecast accuracy would not
be reﬂected in the detection performance measures, thus indicat-
ing faulty formation of the test statistic from the residuals, dis-
cussed in more detail in [19]. The scatter plot in Fig. 4 shows the
relationship between the forecast and detection performance mea-
sures. Each marker represents one of the detection methods ap-
plied to one syndromic time series. A marker’s x-axis value is the
mean absolute residual of the method applied to that time series,
and the y-axis value is the sensitivity of the method for a 20% sig-
nal injection. The models shown are Poisson regression models 1,
2, and 5 and C2 models C2c28 and C2r28. Least-square-ﬁt trend-
lines are plotted for all ﬁve models. The relationship between fore-
cast accuracy and sensitivity is direct but imperfect, and unclear
for small residuals. The scatter plot clariﬁes the minor differences
among models 1 and 5 and the rate-based method C2r28 and, for
mean absolute residuals greater than 10, clearly separates them
from count-based model 2 and C2c28, which have larger residuals
and lower sensitivities.
3.6. Total visits
Inclusion of total visits signiﬁcantly improved both regression
and control-chart methods. This covariate decreased forecast er-
rors by up to 47% (Table 4, model 1 versus model 2 for respiratory),
and improved sensitivity by up to 60% (Table 6, C2r28 versus C2c28
for ILI). The total visits covariate was most effective as a logarith-
mic, additive offset. This approach is essentially a modeling of
the quotient of syndromic and total visit counts (model 5) rathern 0.05 of the best overall forecast method.
Model 1 Model 2 Model 3 Model 4 Model 5 Lowest resi.
2.47 2.70 2.43 2.70 2.38 2.30
6.00 7.01 5.95 7.02 5.74 5.58
7.49 9.04 7.35 9.07 7.40 7.28
7.80 9.96 6.04 9.96 5.88 5.68
16.10 28.29 14.11 28.24 13.85 13.85
5.31 6.24 5.05 6.25 4.92 4.74
11.97 17.65 11.20 17.63 10.94 10.67
3.33 3.66 3.19 3.66 3.10 3.03
5.77 6.97 5.69 6.98 5.53 5.53
8.85 14.41 8.39 14.39 8.39 8.39
19.87 37.81 18.29 37.78 17.81 17.81
3.57 3.91 3.59 3.93 3.52 3.50
7.09 8.02 7.08 8.04 6.88 6.88
16.00 23.00 18.00 23.00 17.00 16.00
Table 4
Empirical thresholds with 1% alert rate for syndrome/mean level combinations for nine study methods.
Syndrome Mean level Threshold
C2c14 C2r14 C2c28 C2r28 Model 1 Model 2 Model 3 Model 4 Model 5
Asthma 1–19 3.215 4.334 3.045 4.081 3.480 3.419 3.551 3.465 3.535
Asthma 20–49 3.542 4.608 3.178 4.605 3.649 3.440 3.788 3.388 3.668
Asthma P50 3.941 4.055 3.613 3.535 3.043 2.894 3.019 2.837 2.910
Gastrointestinal 20–49 3.011 3.448 2.194 3.128 2.521 3.661 2.706 3.679 2.672
Gastrointestinal P50 3.054 3.985 2.640 3.683 2.815 2.881 3.080 2.846 2.990
Nausea and vomiting 20–49 2.937 4.251 2.785 3.681 3.053 3.014 3.005 3.053 3.076
Nausea and vomiting P50 2.983 4.237 2.807 3.859 3.071 3.017 3.332 3.004 3.325
Rash 1–19 3.267 4.360 2.976 3.912 3.216 3.225 3.281 3.238 3.275
Rash 20–49 3.171 4.221 3.111 3.789 3.180 3.049 3.225 3.069 3.046
Rash P50 3.387 4.700 4.033 4.931 3.312 3.108 3.060 3.041 3.180
Respiratory P50 3.445 4.479 2.950 4.392 3.309 3.051 3.519 3.068 3.425
ILI 1–19 3.721 4.994 3.589 4.752 4.251 4.120 4.253 4.105 4.321
ILI 20–49 3.773 5.061 3.639 4.830 5.232 4.618 5.100 4.701 5.072
ILI P50 6.556 6.282 6.360 5.216 4.699 4.825 5.763 4.647 6.207
Table 5
Sensitivity with injection% of moving average of 14-day baseline counts, adjusted by syndrome-MRA mean level. Emboldened values are within 0.01 of the best sensitivity.
Syndrome Inj (%) Mean level Sensitivity
C2c14 C2r14 C2c28 C2r28 Model 1 Model 2 Model 3 Model 4 Model 5 Highest sensitivity
Asthma 80 1–19 0.16 0.17 0.15 0.17 0.16 0.14 0.15 0.13 0.16 0.17
Asthma 80 20–49 0.42 0.58 0.47 0.50 0.60 0.53 0.58 0.55 0.63 0.63
Asthma 80 P50 0.49 0.90 0.54 0.94 0.94 0.88 0.96 0.88 0.97 0.97
Gastrointestinal 40 20–49 0.12 0.31 0.22 0.33 0.30 0.05 0.32 0.05 0.33 0.33
Gastrointestinal 40 P50 0.44 0.70 0.48 0.73 0.71 0.51 0.78 0.52 0.79 0.79
Nausea and vomiting 60 20–49 0.40 0.40 0.40 0.48 0.45 0.39 0.52 0.38 0.51 0.52
Nausea and vomiting 60 P50 0.66 0.84 0.64 0.86 0.84 0.67 0.87 0.68 0.88 0.88
Rash 80 1–19 0.23 0.25 0.25 0.29 0.33 0.27 0.33 0.26 0.33 0.33
Rash 80 20–49 0.53 0.64 0.53 0.70 0.72 0.63 0.74 0.62 0.78 0.78
Rash 80 P50 0.60 0.91 0.42 0.87 0.96 0.72 0.98 0.73 0.98 0.98
Respiratory 40 P50 0.32 0.64 0.36 0.60 0.57 0.46 0.70 0.46 0.73 0.73
ILI 100 1–19 0.17 0.17 0.16 0.18 0.24 0.21 0.24 0.21 0.24 0.24
ILI 100 20–49 0.35 0.56 0.38 0.57 0.43 0.40 0.47 0.38 0.47 0.57
ILI 100 P50 0.18 0.72 0.12 0.75 0.75 0.39 0.57 0.42 0.51 0.75
Table 6
Difference of sensitivity (DS) = (Sensitivity  Highest sensitivity) with injection% of moving average of 14-day baseline counts, adjusted by syndrome-MRA mean level.
Emboldened values are within 0.01 of the highest sensitivity.
Syndrome Inj (%) Mean level C2c14 C2r14 C2c28 C2r28 Model 1 Model 2 Model 3 Model 4 Model 5 Lowest diff.
Asthma 80 1–19 0.01 0.00 0.02 0.00 0.01 0.04 0.02 0.04 0.01 0.00
Asthma 80 20–49 0.21 0.05 0.15 0.12 0.03 0.09 0.04 0.08 0.00 0.00
Asthma 80 P50 0.48 0.07 0.43 0.03 0.03 0.09 0.01 0.09 0.00 0.00
Gastrointestinal 40 20–49 0.22 0.02 0.12 0.00 0.04 -0.28 0.01 0.29 0.00 0.00
Gastrointestinal 40 P50 0.36 0.09 0.31 0.06 0.08 0.28 0.02 0.27 0.00 0.00
Nausea and vomiting 60 20–49 0.12 0.12 0.12 0.03 0.06 0.12 0.00 0.13 0.00 0.00
Nausea and vomiting 60 P50 0.22 0.04 0.24 0.01 0.03 0.20 0.00 0.20 0.00 0.00
Rash 80 1–19 0.10 0.08 0.08 0.05 0.00 0.06 0.00 0.07 0.00 0.00
Rash 80 20–49 0.25 0.14 0.26 0.08 0.06 0.16 0.05 0.16 0.00 0.00
Rash 80 P50 0.38 0.07 0.56 0.11 0.02 0.26 0.00 0.25 0.00 0.00
Respiratory 40 P50 0.42 0.09 0.37 0.14 0.16 0.28 0.03 0.28 0.00 0.00
ILI 100 1–19 0.07 0.07 0.09 0.06 0.00 0.03 0.00 0.03 0.00 0.00
ILI 100 20–49 0.23 0.01 0.19 0.00 0.15 0.17 0.11 0.19 0.10 0.00
ILI 100 P50 0.56 0.02 0.62 0.00 0.00 0.36 0.18 0.33 0.23 0.00
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(models 1 and 3). Regression model 5 is equivalent to modeling
the outcome variable log(syndromic visits per day/total visits per
day). Models 1 and 5 thus differed in the mathematical representa-
tion of total visits. A likely explanation for the effectiveness of the
total visits covariate is that irrelevant but unexpected or difﬁcult-
to-model inﬂuences (e.g. unscheduled closures, holidays) on syn-
dromic visit counts can also affect total visits. Thus, including total
visits may reduce or eliminate these unwanted effects and may
also reduce residual day-of-week effects.4. Discussion
Our goal for this study was to select the most accurate among a
set of time series alerting algorithms for consistent distributed
monitoring in an automated national biosurveillance system. These
algorithms included four control-chart-based methods, which pre-
viously had been found to improve upon the commonly-used EARS
C2 method [5], and ﬁve regression models. The regression models
generally outperformed the control-chart-based methods in both
forecast accuracy and signal sensitivity, though the sensitivity
Fig. 2. Sensitivities for respiratory, with injection = 20%, 40%, 60%, 80% and 100% of moving average of 14-day baseline counts.
Fig. 3. Sensitivities for all diseases/syndromes, with mean level P50, injection = 40%.
R² = 0.163
R² = 0.527
R² = 0.648
R² = 0.168
R² = 0.686
0.0
0.2
0.4
0.6
0.8
1.0
0 20 40 60 80 100 120 140 160
Se
ns
iti
vi
ty
Mean Abs. Residual
Detection (Sensitivity) vs. Prediction (Mean Abs. Residual)
20% Signal Injection
best fit (C2c28)
best fit (C2r28)
best fit (model 1)
best fit (model 2)
best-fit (model 5)
Fig. 4. Scatter plots for comparison of models by both sensitivity and forecast
accuracy for 20% signal injection.
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regression models over the C2-based methods persisted for the
sparse series, i.e. those with mean level 1–19, despite evidence of
occasional overﬁtting. These ﬁndings conﬁrmed those of Jacksonet al. [13] and extended them to a broader set of syndrome types
and data scales and to the inclusion of the total visits variable as
in [3].
The lower percentage injections were useful to compare algo-
rithms using high-count time series for which the higher-percent-
age injections were too easy to detect. The higher percentage
injections were needed to compare algorithms using the lower-
count series for which the lower-percentage injections were too
difﬁcult to detect.
We found general agreement in algorithm evaluation between
the forecast accuracy measure (mean absolute deviation) and the
detection performance measure (sensitivity to ﬁxed-percentage
1-day injections) as shown in scatter plot of Fig. 4 for the 20% sig-
nal injections. This relationship was similar for other injection per-
centages. However, note the considerable dispersion about the
best-ﬁt lines. Recall that each point in the scatter plot represents
forecast accuracy and sensitivity for one algorithm applied to one
syndromic series. Thus, the importance of the dispersion in Fig. 4
and analogous plots is that the same algorithm may have different
sensitivity when applied for different diseases, even at similar data
scales. A likely cause for this dispersion is the use of empirical
alerting thresholds for the sensitivity measurements. As discussed
in the Section 2, the threshold for each algorithmwas chosen as the
J. Xing et al. / Journal of Biomedical Informatics 44 (2011) 1093–1101 110199th percentile of algorithm values in the 1-year training period.
For a training period of 365 days, the 99th percentile is determined
by few data points from a small number of time series for each syn-
drome/mean-level stratum, so that the relevant upper tail of the
algorithm output distribution is not well sampled. For example,
from the superior sensitivity of model 5 for most time series at
mean levels 20–49 and P50, the consistent forecasts in Table 4,
and the limited information available in Table 2 for threshold cal-
culation, the reduced sensitivity of model 5 for ILI is likely a result
of an inefﬁcient threshold value. This last point is important be-
cause of the goal of robust algorithm performance across disease
classiﬁcations and monitoring regions.
Our study is subject to a number of limitations. First, the thresh-
olds are empirically derived from tails of historical algorithm out-
put distributions using a relatively small number of data points. To
address this limitation, we could (a) apply data transformations
that will enable efﬁcient thresholds from a Gaussian or other stan-
dard distribution, (b) seek the number of data series and required
history length in each stratum for reliable empirical thresholds,
and/or (c) apply a hybrid of analytic and empirical threshold deter-
mination methods.
Another study limitation is the injection of single day spikes to
examine detection performance. The practical rationale noted
above is that themethods of this paper, like thosemost widely used
in global practice, are based on single-day anomalies. The combina-
tion of the baseline length and the buffer periodminimizes the con-
tamination of the baseline by earlier parts of any signal that is a
challenge to detect, so we conﬁned our injection to the signal level
on the test day. Themethods discussed here are intended for a mul-
titude of data types in a national system. Developers applying
methods based on speciﬁc signal shapes or on cumulative anoma-
lies may experiment with multiple-day signals.
A possible statistical limitation is the use of the recurrence
interval method for determining background alert rates. This
widely used method is applied with the assumption of negligible
serial correlation in the data series [15]. In view of the wide range
of time series tested, we adopted this method following common
practice in recent biosurveillance studies [13,14], but developers
applying prospective methods to a ﬁxed set of known data streams
should test for serial correlation.
Based on the current study and previous projects and the refer-
ences, we recommend a Poisson regression model adjusting for to-
tal visits as in model 5 for surveillance environments where many
data streams are monitored. The detection performance advantage
of this model compared to a simple adaptive chart such as C2r28
can be over 10% for city-level data. This advantage decreases for
smaller-scale time series in which modeled ﬁxed effects like
weekly patterns are less pronounced. However, but this model re-
tained a slight advantage over C2-based methods even for the
sparse time series. Thus, these results show no penalty for using
regression models across all time series of the types examined in
this study. An important practical consideration is that the empir-
ical threshold determination used in this study should not be ap-
plied indiscriminately in practice, as in the discussion above,
where insufﬁcient or unrepresentative training data may cause a
loss of sensitivity.
Many time series methods could be considered for syndromic
alerting, and we restricted the evaluation to algorithms with
applicability in a health department or other institution monitor-
ing many data sources. In our future study, the algorithms se-
lected for such use should be applicable to many data streams,
some of which have relatively little available history for auto-
mated training and model speciﬁcation. Also, the detection perfor-
mance of the algorithms should be robust to ad hoc changes in
case deﬁnitions deﬁning the time series of interest. Finally, some
transparency in the algorithm methodology is valuable for accep-tance by the health monitoring community; epidemiologists are
reluctant to base investigation and response decisions on black-
box results.
As algorithm comparison studies proliferate, it is important to be
able to compare results among studies quantitatively. Such com-
parisons are difﬁcult because measures for biosurveillance detec-
tion performance are not standardized, and data often cannot be
shared for proprietary, contractual, or privacy reasons. For example,
we report general agreement with the results of Jackson et al. [13],
but direct comparison of the sensitivity results would require the
time series data used in that paper. Purely simulated data are share-
able or replicable, but algorithm results on such data have the dis-
advantage that they may not transfer to authentic nonstationary
data. Section 2.4 of [20], supported by commentaries from various
other authors, discusses at length the issues of surveillance research
replicability and authentic data availability. It would beworthwhile
to overcome obstacles to institutional data sharing for research to
enable detailed, objective study comparisons.
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